Machine learning approaches to drug response prediction: challenges and recent progress
- PMID: 32566759
- PMCID: PMC7296033
- DOI: 10.1038/s41698-020-0122-1
Machine learning approaches to drug response prediction: challenges and recent progress
Abstract
Cancer is a leading cause of death worldwide. Identifying the best treatment using computational models to personalize drug response prediction holds great promise to improve patient's chances of successful recovery. Unfortunately, the computational task of predicting drug response is very challenging, partially due to the limitations of the available data and partially due to algorithmic shortcomings. The recent advances in deep learning may open a new chapter in the search for computational drug response prediction models and ultimately result in more accurate tools for therapy response. This review provides an overview of the computational challenges and advances in drug response prediction, and focuses on comparing the machine learning techniques to be of utmost practical use for clinicians and machine learning non-experts. The incorporation of new data modalities such as single-cell profiling, along with techniques that rapidly find effective drug combinations will likely be instrumental in improving cancer care.
Keywords: Combination drug therapy; High-throughput screening; Pharmacogenetics.
© The Author(s) 2020.
Conflict of interest statement
Competing interestsThe authors declare no competing interests.
Figures

References
-
- Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 10.3322/caac.21492 (2018). - PubMed
-
- Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J. Clin. Oncol. 2013;31:1803–1805. - PubMed
-
- Doherty M, Metcalfe T, Guardino E, Peters E, Ramage L. Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways. Ann. Oncol. 2016;27:1644–1646. - PubMed
-
- Heymach J, et al. Clinical Cancer Advances 2018: annual report on progress against cancer from the American Society of Clinical Oncology. J. Clin. Oncol. 2018;36:1020–1044. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources